Current Report Filing (8-k)
May 02 2016 - 5:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
April
28, 2016
|
Date of report (Date of earliest event reported)
|
SurModics, Inc.
|
(Exact Name of Registrant as Specified in its Charter)
|
Minnesota
|
|
0-23837
|
|
41-1356149
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
9924 West 74
th
Street
Eden Prairie, Minnesota
|
|
55344
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(952) 500-7000
|
(Registrant’s Telephone Number, Including Area Code)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(see General Instruction A.2):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02 Results of Operations And Financial Condition.
On May 2, 2016, SurModics, Inc. (the “
Company
”) issued a
press release (the “
Press Release
”) announcing the results
for the quarter ended March 31, 2016. A copy of the full text of the
Press Release is furnished as Exhibit 99.1 to this report.
The information contained in this Item 2.02, including Exhibit 99.1,
shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall they be deemed to
be incorporated by reference into any filing under the Securities Act of
1933, as amended, except as shall be expressly set forth by specific
reference in such a filing.
Item 8.01 Other Items.
In connection with the preparation of the financial statements for the
fiscal quarter ended March 31, 2016, the Company became aware of royalty
overpayments made by customers pursuant to license agreements for
products incorporating certain of the Company’s technologies no longer
covered by an unexpired patent. The Company did not identify that
certain amounts reported by the customers were not in accordance with
the terms of the license agreement and should have been deferred or
refunded to the customers, resulting in an overstatement of
revenue. These misstatements resulted in an estimated cumulative
overstatement of royalty revenue of approximately $1.1 million, of which
$1.0 million relates to periods from fiscal 2012 to fiscal 2015. These
misstatements were not material to any prior period; accordingly, prior
periods will not be restated. The Company’s financial results for the
fiscal quarter ended March 31, 2016, include an out-of-period adjustment
to correct this cumulative overstatement of royalty revenue.
Following the identification of the cumulative royalty overpayments
noted above, the Company’s Chief Executive Officer and Chief Financial
Officer re-evaluated the effectiveness of internal control over
financial reporting based on the framework in
Internal Control
—
Integrated
Framework (2013)
issued by the Committee of Sponsoring Organizations
of the Treadway Commission as of September 30, 2015 and December 31,
2015, and determined that a material weakness existed in the design and
operating effectiveness of the Company’s controls related to the
recognition of royalty revenue, specifically the controls to ensure that
royalty revenue is accurate and complete. As a result, the Company’s
Chief Executive Officer and Chief Financial Officer concluded that the
Company’s internal control over financial reporting was not effective as
of September 30, 2015 and December 31, 2015. The Company expects to
file an amendment with the Securities and Exchange Commission to its (a)
Annual Report on Form 10-K for the year ended September 30, 2015,
amending and revising Item 9A of Part II, “Controls and Procedures,”
with respect to (1) the Company’s conclusions regarding the
effectiveness of its disclosure controls and procedures and its internal
control over financial reporting, and (2) Deloitte & Touche LLP’s
related attestation report, and (b) Quarterly Report on Form 10-Q for
the fiscal quarter ended December 31, 2015, with respect to the
Company’s conclusions regarding the effectiveness of its disclosure
controls and procedures as a result of a material weakness in internal
control over financial reporting. Management is taking steps to address
the Company’s controls related to the recognition of royalty revenue,
including the accuracy and completeness of royalty reporting and
payments made by customers pursuant to license agreements for products
incorporating the Company’s technologies no longer covered by an
unexpired patent. Management plans to implement additional measures to
remediate the underlying causes of the material weakness described above.
The Company’s management and the Committee have discussed the matters
disclosed in this filing with Deloitte & Touche LLP, the Company’s
independent registered public accounting firm.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
.
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press Release dated May 2, 2016.
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SURMODICS, INC.
|
|
|
|
|
|
|
Date:
|
May 2, 2016
|
|
/s/ Andrew D. C. LaFrence
|
|
|
|
Andrew D. C. LaFrence
|
|
|
|
Vice President Finance and Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
|
|
|
|
Number
|
|
Description
|
|
99.1
|
|
Press Release dated May 2, 2016.
|
|
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2023 to Apr 2024